Abstract
Today biomarkers are used widely across the drug development continuum to improve the success rate and cost-effectiveness of rational drug development [1, 2]. These include diagnostic indicators of disease, assessments for biological pathways for new therapeutics, confirmation of target engagement or mechanism-of-action, safety indicators, and as pharmacodynamic (PD) measures of therapeutic efficacy [1, 2]. The application of biomarkers is now commonplace in drug development and has helped usher in a new era of predictive, preventative, and personalized medicine, where therapeutics can be tailored to a patient’s unique biology. However, prior to being used for these purposes, there are several practical aspects of biomarker utilization that need to be taken into account. These include biomarker validation and qualification. Analytical validation is the formal process of evaluating an assay to ensure it provides reliable data [1, 2], whereas qualification (also known as clinical validation) is the evidentiary process of linking a biomarker with biology, pharmacology, or clinical endpoint [1, 2]. Analytical validation is important, as issues of quality herein can limit the utility of biomarker data. Moreover, a lack of proper analytical validation can potentially undermine successful demonstration of a biomarker-related pharmacodynamic effect during clinical investigation [1, 2]. Not surprisingly, successful biomarker testing in drug development requires careful consideration of pre-analytical factors that may impact reliable biomarker quantification in biological matrices. Most often, pre-analytical factors include activities associated involving collection, shipment, tracking, storage, and distribution of test samples. Analytical considerations include the use of kits versus custom assays, reference standard sourcing, sample preparation strategies [3, 4], instrumentation and the removal of matrix interferences. This chapter will discuss some of the various factors that need to be taken into account when preparing for biomarker analysis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bowsher R, Nowatzke W (2012) Application of commercial research-grade biomarker assays in drug development: is it time to create ‘pharmaceutical grade’ kits? Bioanalysis 4(20):2427–2430
Nowatzke W, Cole T, Bowsher R (2012) Systemic analytical validation of commercial kits for the determination of novel biomarkers for clinical drug development. Bioanalysis 2(2):237–247
Tuck M et al (2013) Serum and plasma collection: preanalytical variables and standard operating procedures in biomarker research. Proteominc Metab Approaches Biomark Discov Chap 5:78–85
Ye X et al (2013) Tissue sample preparation for proteomic analysis. Proteominc Metab Approaches Biomark Discov Chap 3:40–49
Lee JW et al (2006) Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 23(2):312–328
Holland N, Bastaki M et al (2005) Molecular epidemiology biomarkers—sample collection and processing considerations. Toxicol Appl Pharmacol 206:261–268
Tworoger S, Hankinson S et al (2006) Collection, processing, and storage of biological samples in epidemiologic studies: sex hormones, carotenoids, inflammatory markers, and proteomics as examples. Cancer Epidemiol Biomark Prev 15:1578–1581
Campbell L (2012) Best practices for repositories: collection, storage, retrieval and distribution of biological materials for research. Biopreservation Biobanking 10:81–161
National Metrology Laboratory (2012) User guide to mapping temperature controlled enclosures 4:1–8
Wagar EA, Stankovic AK, Raab S, Nakhleh RE, Walsh MK (2008) Specimen labeling errors: a Q-probes analysis of 147 clinical laboratories. Arch Pathol Lab Med 132(10):1617–1622
Tate J, Ward G (2004) Interferences in immunoassays. Clin Biochem Rev 25:105–120
Selby C (1999) Interference in immunoassay. Ann Clin Biochem 36:704–721
Kricka L (1999) Human anti-animal antibody interferences in immunological assays. Clin Chem 45:942–956
Hamilton RG, Adkinson NF (1985) Naturally occurring carbohydrate antibodies: interference in solid-phase immunoassays. J Immunol Methods 77:95–108
Adedoyin J, Johansson SGO, Gronlund H, van Hage M (2006) Interference in immunoassays by human IgM with specificity for the carbohydrate moiety of animal proteins. J Immunol Methods 310:117–125
Levinson SS, Miller JJ (2002) Towards a better understanding of heterophile (and the like) antibody interferences with modern immunoassays. Clin Chim Acta 325:1–15
Bouvet JP, Quan CP, Dighiero G (2002) Polyreactivity is not an artifact. J Immunol Methods 254:199–201
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Davis, R.A., Mayer, A.P., Bowsher, R.R. (2016). Biomarkers in Drug Discovery and Development: Pre-analytical and Analytical Considerations. In: Weiner, R., Kelley, M. (eds) Translating Molecular Biomarkers into Clinical Assays . AAPS Advances in the Pharmaceutical Sciences Series, vol 21. Springer, Cham. https://doi.org/10.1007/978-3-319-40793-7_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-40793-7_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-40792-0
Online ISBN: 978-3-319-40793-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)